Vivos Therapeutics (VVOS) FCF Margin Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -80.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 473.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -192.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -431.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1,716.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2,833.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2,811.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -125.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | 1,298.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,298.00 |
| Dec 31, 2025 | -12,861.00 |
| Sep 30, 2025 | 5,182.00 |
| Jun 30, 2025 | -3,425.00 |
| Mar 31, 2025 | -5,203.00 |
| Dec 31, 2024 | 2,217.00 |
| Sep 30, 2024 | -4,084.00 |
| Jun 30, 2024 | 1,944.00 |
| Mar 31, 2024 | 1,505.00 |
| Dec 31, 2023 | -2,503.00 |
| Sep 30, 2023 | 6,827.00 |
| Jun 30, 2023 | 2,650.00 |
| Mar 31, 2023 | 7,715.00 |
| Dec 31, 2022 | 2,116.00 |
| Sep 30, 2022 | -4,197.00 |
| Jun 30, 2022 | -1,120.00 |
| Mar 31, 2022 | -5,062.00 |
| Dec 31, 2021 | 978.00 |
| Sep 30, 2021 | -7,712.00 |
| Jun 30, 2021 | -8,300.00 |